VistaGen Therapeutics(VTGN) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Vistagen to Participate in Stifel 2025 Virtual CNS Forum
BusinesswireMar 4 08:30 ET
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsFeb 20 10:31 ET · Ratings
Positive Outlook on VistaGen Therapeutics Driven by Promising Clinical Developments and Solid Financial Position
TipRanksFeb 20 10:25 ET
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
BusinesswireFeb 20 08:30 ET
Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations
Yahoo FinanceFeb 15 07:33 ET
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q3 2025 Earnings Conference
moomoo AIFeb 13 21:03 ET · Conference Call

Comments

Trytosaveabit

Feb 14 05:46

Not to shabby

$VistaGen Therapeutics (VTGN.US)$ VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 109.09 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent. This is a 43.12 percent decrease over sales of $411.40 thousand th...

Teddy123

Feb 5 21:38

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

$VistaGen Therapeutics (VTGN.US)$
Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin

Trytosaveabit

Feb 5 21:32

ne2s

$VistaGen Therapeutics (VTGN.US)$ Reuters· just
Vistagen Receives U.S. Patent for Av-101 to Treat Neuropathic Pain

1

Jaguar8

Feb 5 21:30

NEWS

$VistaGen Therapeutics (VTGN.US)$
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Wednesday, 5th February at 8:30 am
Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatmen...

2

幹完這一筆就退休了

Jan 16 22:57

$VistaGen Therapeutics (VTGN.US)$ coming?

VTGN VistaGen Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks